iifl-logo

Sun Pharmaceuticals Industries Ltd Nine Monthly Results

1,616.6
(0.43%)
Sep 12, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Dec-2024Dec-2023Dec-2022Dec-2021Dec-2020

Gross Sales

39,225.67

35,945.12

32,553.3

29,040.34

24,769.34

Excise Duty

0

0

0

0

0

Net Sales

39,225.67

35,945.12

32,553.3

29,040.34

24,769.34

Other Operating Income

393.93

568.83

401.71

167.39

205.82

Other Income

1,352.17

748.25

261.24

807.92

1,012.8

Total Income

40,971.77

37,262.2

33,216.25

30,015.65

25,987.96

Total Expenditure

28,380.17

26,918.65

24,110.35

21,781.45

22,165.56

PBIDT

12,591.6

10,343.55

9,105.9

8,234.2

3,822.4

Interest

182.22

164.9

79.26

90.01

111.33

PBDT

12,409.38

10,178.65

9,026.64

8,144.19

3,711.07

Depreciation

1,911.6

1,906.28

1,857.9

1,587.27

1,526.46

Minority Interest Before NP

0

0

0

0

0

Tax

1,678.32

1,290.52

624.68

928.74

747.93

Deferred Tax

0

0

0

0

0

Reported Profit After Tax

8,819.46

6,981.85

6,544.06

5,628.18

1,436.68

Minority Interest After NP

31.66

29.49

40.93

66.68

-579.73

Net Profit after Minority Interest

8,779.16

6,921.8

6,489.11

5,549.98

2,009.67

Extra-ordinary Items

-265.62

-331.42

0

-541.68

-1,912.03

Adjusted Profit After Extra-ordinary item

9,044.78

7,253.22

6,489.11

6,091.66

3,921.7

EPS (Unit Curr.)

36.6

28.8

27

23.1

8.38

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

1,050

850

750

700

550

Equity

239.93

239.93

239.93

239.93

239.93

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

32.1

28.77

27.97

28.35

15.43

PBDTM(%)

31.63

28.31

27.72

28.04

14.98

PATM(%)

22.48

19.42

20.1

19.38

5.8

Sun Pharma.Inds.: Related NEWS

Top Stocks for Today - 10th September 2025

Here are some of the stocks that may see significant price movement today: Bajaj Auto, Sterling & Wilson Renewable, Vodafone Idea, etc.

10 Sep 2025|07:25 AM
Read More
Top Stocks for Today - 15th July 2025

Here are some of the stocks that may see significant price movement today: Power Mech Projects, Rail Vikas Nigam, Rallis India, etc.

15 Jul 2025|06:24 AM
Read More
Top Stocks for Today - 16th June 2025

Here are some of the stocks that may see significant price movement today: Sun Pharma, Vedanta, SpiceJet, etc.

16 Jun 2025|06:23 AM
Read More
US FDA Flags 8 Observations at Sun Pharma’s Halol Facility After GMP Inspection

The visit lasted from June 2 to June 13 and focused on checking for compliance with Good Manufacturing Practices.

15 Jun 2025|11:50 PM
Read More
Sun Pharma Expands Specialty Drug Pipeline with $25 Million Pharmazz Deal

Both treatments have already received approvals in India and are available for sale there with local partners under a brand known as Tyvalzi and Lyfaquin.

24 May 2025|07:51 PM
Read More
Sun Pharma Q4 FY25 Revenue Rises 8.5% to ₹12,816 Crore

The Board recommended a final dividend of ₹5.50 per share for FY25.

23 May 2025|12:07 PM
Read More
Top Stocks for Today - 7th May 2025

NLC's subsidiary has executed a PPA with Rajasthan Rajya Vidyut Utpadan Nigam Ltd. (RVUNL) for 810 MW solar power plant at Pugal Solar Park, Rajasthan

7 May 2025|08:06 AM
Read More
Sun Pharma’s MM-II Trial Shows Long-Lasting Relief for Knee Osteoarthritis

Based on the Phase 2b clinical trial, the study used a randomised, double-blind, placebo-controlled design that yielded strong and dependable data.

26 Apr 2025|01:15 PM
Read More
Sun Pharma to Acquire Nasdaq-Listed Checkpoint Therapeutics for $355 Million

The deal is expected to be completed in the second quarter of 2025, subject to customary closing conditions and regulatory approvals.

10 Mar 2025|10:46 AM
Read More
Sun Pharma Q3 Profit Jumps 19% YoY, Declares ₹10.50 Dividend

An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.

31 Jan 2025|10:17 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.